Drug Trial Radar · NCT06462612
Study of Lumateperone in the Treatment of Patients With Bipolar Mania
Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
351
Actual
Start
Jul 17, 2024
Primary completion
May 15, 2026
Study completion May 20, 2026
Sponsor
- Lead sponsor
- Intra-Cellular Therapies, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with or without psychotic symptoms, according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).
Conditions
- Bipolar Disorder, Manic
Interventions
LumateperoneDrug
Lumateperone 42 mg capsules administered orally, once daily
PlaceboDrug
Matching capsules administered orally, once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Young Mania Rating Scale (YMRS)Time frame: Week 3
Locations
35 sites in 4 countries. Site status is shown where the registry gives one.
Clinical Site
Bentonville, Arkansas
Clinical Site
Little Rock, Arkansas
Clinical Site
Anaheim, California
Clinical Site
Cerritos, California
Clinical Site
Orange, California
Clinical Site
Torrance, California
Clinical Site
Hialeah, Florida
Clinical Site
Miami, Florida
Clinical Site
Miami, Florida
Clinical Site
Miami, Florida
Clinical Site
Miami Lakes, Florida
Clinical Site
Miami Lakes, Florida
Clinical Site
Tampa, Florida
Clinical Site
West Palm Beach, Florida
Clinical Site
Atlanta, Georgia
Clinical Site
Stockbridge, Georgia
Clinical Site
Chicago, Illinois
Clinical Site
Chicago, Illinois
Clinical Site
Gaithersburg, Maryland
Clinical Site
Glen Oaks, New York
Clinical Site
Cincinnati, Ohio
Clinical Site
Richardson, Texas
Clinical Site
Burgas, Bulgaria
Clinical Site
Kazanlak, Bulgaria
Clinical Site
Plovdiv, Bulgaria
Clinical Site
Sliven, Bulgaria
Clinical Site
Sofia, Bulgaria
Clinical Site
Brasov, Romania
Clinical Site
Bucharest, Romania
Clinical Site
Iași, Romania
Clinical Site
Belgrade, Serbia
Clinical Site
Kovin, Serbia
Clinical Site
Kragujevac, Serbia
Clinical Site
Niš, Serbia
Clinical Site
Novi Kneževac, Serbia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.